Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)

Summary

This is a randomized, double-blind, placebo-controlled, Phase 2, 12-Week treatment study with a 10-Week Follow-up period to assess the efficacy and safety of Benralizumab (anti-IL5Rα) in adult patients with chronic prurigo (BICPIC)

Timeline

Start

2023-10

Primary completion

2023-10-19

Completion

2023-10-19

Outcome

Outcome not reported

Stopped (Business): “Financing has been withdrawn”

Drugs

Indications